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The genetic architecture of schizophrenia is likely contributed
by both common and rare variants.1 Recent genome-wide
studies have revealed that common variants in the major
histocompatibility complex (MHC) region, TCF4 and other genes
are associated with schizophrenia.1 In addition, rare copy-number
variation (CNV) regions in broad regions like 1q21.1, 15q13.3,
15q11.2, 22q111 as well as individual genes such as Neurexin2,3
have been identiﬁed. Unbiased exome or whole genome scanning
procedures have the potential to identify novel loci while
likely requiring large sample sets to reach a genome-wide
signiﬁcance level. It is possible that the previously identiﬁed
genes/regions from high-throughput single-nucleotide poly-
morphisms (SNP) chip genome-wide scanning techniques, in
contrast to some ‘classical’ candidate genes,4 may harbor rare
coding variants that have a role in disease risk. We selected a total
of 101 genes from within the 1q21.1, 15q13.3, 22q11 and 15q11.2
regions and a number of other candidate genes, with either a
priori knowledge for association with schizophrenia, for example,
TCF4/CCDC68, NRXN1, or interesting for drug-discovery efforts,
for example, cyclic nucleotide phosphodiesterase genes, and
surveyed rare variants in their coding regions through deep
sequencing.
Our sample set included cases who met DSM-IV criteria for
schizophrenia. All subjects provided informed consent that was
approved by the ethics committees at the speciﬁc sites. Our
discovery set included 525 schizophrenia cases (68% male cases,
69 cases were diagnosed with schizophrenia before 18 years of
age) and 619 controls (62% male cases) without any neurological
and psychiatric disorders and were primarily collected during
Pﬁzer clinical trials. The replication set includes 455 schizophrenia
subjects (71% male subjects) and 336 controls (73.5% male
subjects), collected at the Universities of Edinburgh and Aberdeen.
Only Caucasian subjects were included in our study to reduce the
sample heterogeneity.
Coding sequences in our target regions were enriched
using the Nimblegen capture array, followed by Illumina HiSeq
paired-end sequencing at the Beijing Genome Institute
(BGI Inc.). We pooled 48 bar-coded samples together before the
sequencing run. In total, we obtained 149Mb of sequencing
data in which over 98.5% of reads mapped to our regions of
interest. The mean read depth was 96 × , which is much
higher than the estimated average depth (33 × ) required
for highly accurate downstream heterozygous variant
detection. After removing genes with low coverage that failed
the capture design, over 95.3% of the bases in our targeted
regions were covered with genotype data at least 30 × to
ensure variant detection sensitivity. The variants have a greater
than 99.6% concordance rate with available genome-wide
genotyping data.
A total of 7072 and 5170 novel variants were identiﬁed in the
discovery and replication sets, respectively (we excluded all Indel
calls, which may have a higher false-positive rate). Approximately,
70% of the variants are not common in the population (minor
allele frequency number no greater than 1%). In both data sets, we
found a variety of SNPs including intronic, missense, synonymous
and UTR variants as well as splice variants and nonsense SNPs
(Table 1). We observed approximately two fold rare (minor allele
frequency number greater than 0.5%) nonsense alleles in cases
compared with the nonsense alleles in controls (one-sided P-
value = 0.056, odd ratio (OR) = 1.96). In contrast, we observed
about equal frequencies of rare synonymous variants in cases and
controls in the identical genomic regions for the same cohorts
(one-sided P40.1, OR = 1.08), suggesting that it is unlikely that the
result is due to sampling bias. Furthermore, the proportion of
ultra-rare ‘deleterious’ variants in the CNV regions is signiﬁcantly
higher in early-onset schizophrenia cases (age of onset less than
18 years) versus that in the controls in the study (nonsense plus
splicing one-sided P-value = 0.09, OR= 3.41; including conserved
Table 1. Variants identiﬁed in the two independent cohorts
Discovery (case = 525, control = 619) Replication (case = 456, control = 336)
Variant typea Novel dbSNP MAF⩽ 1%b Case only Control only Case and
control
Novel dbSNP MAF⩽ 1%b Case only Control only Case and
control
Downstream 72 57 92 27 39 63 69 56 80 32 27 66
Intergenic 64 49 89 39 30 44 54 29 63 30 17 36
Intronic 4001 3143 4967 1706 2066 3372 2953 2846 3512 1540 1130 3129
ncRNA 303 258 350 129 129 303 236 228 264 111 75 278
Nonsynonymous 812 241 918 323 412 318 596 193 642 304 203 281
Splicing 31 11 33 12 18 12 18 8 17 10 4 12
Stop codon 16 3 15 9 5 5 11 3 10 7 1 6
Synonymous 600 305 733 246 320 339 381 247 452 215 131 282
Upstream 67 46 77 25 35 53 74 51 82 36 32 57
UTR3 925 425 1067 370 415 565 649 360 719 320 228 461
UTR5 181 59 203 47 97 96 130 56 145 67 37 82
Abbreviations: dbSNP, single-nucleotide polymorphism database; MAF, minor allele frequency. aTranscripts from ENSEMBL V63 were used to annotate these
variants. bMAF less than or equal to 1% in each of the cohorts.
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damaging missense variants: one-sided P= 0.02, OR= 1.88),
supporting the ﬁnding that rare variants may contribute to
schizophrenia etiology. None of the rare nonsense variants
identiﬁed in this study were listed in dbSNP (version 132).
Intriguingly, different stop codons in NRXN1 were observed in two
individuals with schizophrenia from two independent cohorts but
were not observed in any of the controls, suggesting that rare
loss-of-function events in NRXN1, either through deletion or
through nonsense mutation, could be important in the etiology of
schizophrenia (Supplementary Table S1).
Most of the rare variants only occur once or twice in our cohort,
which limits the statistical power to detect the association in
individual variants. We therefore conducted aggregate analysis
across all functional variants within each gene by comparing
carrier frequencies between cases and controls to understand
whether the gene as a whole has a consistent effect across the
discovery and replication data sets. We focused on functional
variants with a minor allele frequency no higher than 1% in
controls in our analysis.
Among the 84 genes with at least one rare functional
variant tested in both sample sets, 48 genes showed a consistent
pattern of frequency distribution (Supplementary Table S2)
although none of these associations passed the multiple test
correction. Among these 48 genes, a majority of genes (30)
showed an elevated frequency of rare variants in cases compared
with controls, including the TCF4 gene. Common SNPs in
TCF4 have emerged from the schizophrenia genome-wide
association study (GWAS) consortia and conﬁrmed to be
associated, at genome-wide levels of signiﬁcance, with the
disease risk1,5. Furthermore, one of the SNPs (rs9960767) has
been linked to deﬁcits in sensorimotor gating,6 and the expression
levels of TCF4 were shown to be increased in patients
with psychosis7 and be under the regulation of the
schizophrenia-linked miRNA-137.8 Rare mutations in TCF4 have
been previously identiﬁed in autosomal dominant forms of the
Pitt–Hopkins syndrome, a disorder characterized by severe motor
and mental retardation and susceptibility to childhood-onset
seizures.9 A total of seven distinct rare functional variants in
TCF4 were identiﬁed in our two cohorts; intriguingly, they
do not overlap with the known Pitt–Hopkins-associated
variants (Supplementary Table S3). Three different variants
were identiﬁed in the discovery cohort, with one variant
(chr18:52928743:G_A) carried by three sporadic schizophrenia
cases. Five variants occurred in the replication cohort and
they all appeared in cases. The variant chr18:52928743:G_A is
observed in a total of ﬁve schizophrenia cases and one control
across the two cohorts. The same variant has a consis-
tently rare frequency in the large general population (9/6494
from the Exome Variant server; 1/947 in our controls) and
is lower than what we observed in the schizophrenia s
ubjects (5/922). TCF4 is a complex gene with multiple transcripts
with variation in their N-termini.10 The C terminus is shared
between variants with a conserved basic helix-loop-helix
domain, which is critical for dimerization (homo-, hetero-), DNA
binding at Eprussi box (E-box) sequences and transcrip-
tional activation. Intriguingly, Pitt–Hopkins mutations congre-
gate in these C-terminal domains and have been shown to
differentially impact these functions. The mutations we have
identiﬁed are principally in the N-terminal domains, and
depending on the different exons spliced into a speciﬁc transcript
these may have impact on processes such as sub-
cellular localization as well as protein–protein and protein–DNA
interactions. Although beyond the scope of this work, it will
be important to understand the functional impact of these
identiﬁed variants in the context of transcripts expressed in the
schizophrenic brain.
In summary, the study suggests that the current candidate genes
obtained from unbiased GWAS and CNV scanning reports do harbor
rare functional variants in sporadic schizophrenia patients. We observed
an overall enrichment for damaging variants, especially nonsense
variants. In particular, a similar effect was observed in early-onset cases.
Together, this supports our hypothesis that rare coding (for example,
loss of function) variants in deletion/SNP regions from previous
genome-wide scanning reports may also contribute to the genetic
architecture of schizophrenia. The sample sizes in the study limit our
ability to pinpoint speciﬁc genes/variants but the identiﬁed variants,
especially in NXRN1 and TCF4, will be helpful in future functional
genomic investigations of the genes and related biological pathways.
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